CDK4 and diffuse intrinsic pontine glioma: DeWire et al. conducted a phase I trial to determine the tolerability and efficacy of Ribociclib (CDK4/6-inhibitor) and Everolimus (kinase inhibitor) for patients newly diagnosed with DIPG within 30 days of receiving a 10% standard dose of radiotherapy [27].